Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/205831
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Recombinant poxviruses as mucosal vaccine vectors |
Autor: | Gherardi, Magdalena; Esteban, Mariano CSIC ORCID | Fecha de publicación: | 2005 | Editor: | Society for General Microbiology | Citación: | Journal of General Virology 86: 2925-2936 (2005) | Resumen: | The majority of infections initiate their departure from a mucosal surface, such as Human immunodeficiency virus (HIV), a sexually transmitted virus. Therefore, the induction of mucosal immunity is a high priority in the development of vaccines against mucosal pathogens. The selection of an appropriate antigen delivery system is necessary to induce an efficient mucosal immune response. Poxvirus vectors have been the most intensively studied live recombinant vector, and numerous studies have demonstrated their ability to induce mucosal immune responses against foreign expressed antigens. Previous studies have demonstrated that recombinants based on the attenuated modified vaccinia virus Ankara (MVA) vector were effective in inducing protective responses against different respiratory viruses, such as influenza and respiratory syncytial virus, following immunization via mucosal routes. Recent studies performed in the murine and macaque models have shown that recombinant MVA (rMVA) does not only stimulate HIV-specific immunity in the genital and rectal tracts following mucosal delivery, but can also control simian/human immunodeficiency viraemia and disease progression. In addition, a prime-boost vaccination approach against tuberculosis emphasized the importance of the intranasal rMVA antigen delivery to induce protective immunity against Mycobacterium tuberculosis. The aim of this review is to summarize the studies employing recombinant poxviruses, specifically rMVA as a mucosal delivery vector. The results demonstrate that rMVAs can activate specific immune responses at mucosal surfaces, and encourage further studies to characterize and improve the MVA mucosal immunogenicity of poxvirus vectors. | Versión del editor: | http://dx.doi.org/10.1099/vir.0.81181-0 | URI: | http://hdl.handle.net/10261/205831 | DOI: | 10.1099/vir.0.81181-0 | Identificadores: | doi: 10.1099/vir.0.81181-0 issn: 0022-1317 e-issn: 1465-2099 |
Aparece en las colecciones: | (CNB) Artículos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
71
checked on 21-abr-2024
WEB OF SCIENCETM
Citations
68
checked on 25-feb-2024
Page view(s)
208
checked on 24-abr-2024
Download(s)
44
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.